Ferric carboxymaltose in patients with heart failure and iron deficiency

New England Journal of Medicine

Volumn 361, Issue 25, 2009, Pages 2436-2448

  Anker, Stefan D ^a,b   Colet, Josep Comin ^c   Filippatos, Gerasimos ^d   Willenheimer, Ronnie ^e   Dickstein, Kenneth ^f,g   Drexler, Helmut ^h   Lüscher, Thomas F ⁱ   Bart, Boris ^l   Banasiak, Waldemar ^m   Niegowska, Joanna ⁿ   Kirwan, Bridget Anne ^j   Mori, Claudio ^k   Von Eisenhart Rothe, Barbara E ^k   Pocock, Stuart J ^p   Poole Wilson, Philip A ^q   Ponikowski, Piotr ^m,o  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Centre for Clinical and Basic Research   (Italy)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^e LUND UNIVERSITY   (Sweden)

^f STAVANGER UNIVERSITY HOSPITAL   (Norway)

^g UNIVERSITY OF BERGEN   (Norway)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^j SOCAR RESEARCH SA   (Switzerland)

^k Vifor (International) Inc   (Switzerland)

^l PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^m MILITARY HOSPITAL   (Poland)

ⁿ Telmont Centrum Medyczne Sp z OO   (Poland)

^o WROCLAW MEDICAL UNIVERSITY   (Poland)

^p LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^q NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ASPARTATE AMINOTRANSFERASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CREATININE; DIGITALIS GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FERRIC CARBOXYMALTOSE; FERRITIN; HEMOGLOBIN; INSULIN; IRON DERIVATIVE; ORAL ANTIDIABETIC AGENT; PLACEBO; POTASSIUM; SODIUM; SODIUM CHLORIDE; TRANSFERRIN; UNCLASSIFIED DRUG;

ABNORMAL LABORATORY RESULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG FATALITY; FEMALE; FERRITIN BLOOD LEVEL; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; INFESTATION; INJECTION SITE DISCOLORATION; INJECTION SITE PAIN; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON DEPLETION; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; MEDIASTINUM DISEASE; NEUROLOGIC DISEASE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SELF REPORT; SIDE EFFECT; SODIUM BLOOD LEVEL; THORAX DISEASE; TRANSFERRIN BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; VITAL SIGN; WALKING;

EID: 72449156527     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0908355     Document Type: Article

References (25)

1. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53(15):e1-e90.
2. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology: developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-989
3. Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348:2007-2018
4. Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA 2004;292:344-350 (Pubitemid 38944258)
5. Clark AL, Poole-Wilson PA, Coats AJ. Exercise limitation in chronic heart failure: central role of the periphery. J Am Coll Cardiol 1996;28:1092-1102 (Pubitemid 26376979)
6. Massie BM, Conway M, Rajagopalan B, et al. Skeletal muscle metabolism during exercise under ischemic conditions in congestive heart failure: evidence for abnormalities unrelated to blood flow. Circulation 1988;78:320-326 (Pubitemid 18195040)
7. Tang YD, Katz SD. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 2006;113:2454-2461
8. Dunn LL, Rahmanto YS, Richardson DR. Iron uptake and metabolism in the new millennium. Trends Cell Biol 2007;17:93-100.
9. Fairbanks V, Beutler E. Iron deficiency. In: Beutler E, ed. Williams hematology. 6th ed. New York: McGraw-Hill, 2001:295-304, 447-470
10. Beard JL. Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr 2001;131:Suppl 2: 568S-579S.
11. Haas JD, Brownlie T IV. Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J Nutr 2001;131:Suppl 2:676S-688S.
12. Davies KJ, Maguire JJ, Brooks GA, Dallman PR, Packer L. Muscle mitochondrial bioenergetics, oxygen supply, and work capacity during dietary iron deficiency and repletion. Am J Physiol 1982;242(6):E418-E427.
13. Satija P, Ondo WG. Restless legs syndrome: pathophysiology, diagnosis and treatment. CNS Drugs 2008;22:497-518. (Pubitemid 351693691)
14. Opasich C, Cazzola M, Scelsi L, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 2005;26:2232-2237 (Pubitemid 41541385)
15. Nanas JN, Matsouka C, Karageorgopoulos D, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 2006;48:2485-2489 (Pubitemid 44881220)
16. Bolger AP, Bartlett FR, Penston HS, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 2006;48:1225-1227 (Pubitemid 44345150)
17. Okonko DO, Grzeslo A, Witkowski T, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008;51:103-112
18. Toblli JE, Lombraña A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro- brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 2007;50:1657-1665 (Pubitemid 47562670)
19. Usmanov RI, Zueva EB, Silverberg DS, Shaked M. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol 2008;21:236-242
20. Anker SD, Colet JC, Filippatos G, et al. Rationale and design of Ferinject Assessment in patient with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomised, placebo controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail 2009;11:1084-1091
21. Ganzoni AM. Intravenous iron-dextran: therapeutic and experimental possibilities. Schweiz Med Wochenschr 1970;100:301-303 (In German.)
22. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 2000;35:1245-1255
23. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337-343 (Pubitemid 32675374)
24. McCullagh P. Regression models for ordinal data (with discussion). J R Stat Soc [B] 1980;42:109-142
25. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc [B] 1995;57:289-300.